Active Ingredient(s): Dapagliflozin + Saxagliptin
FDA Approved: * February 27, 2017
Pharm Company: * ASTRAZENECA AB
Category: Diabetes

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Qtern Overview

Dapagliflozin (INN,[2] USAN,[3] trade name Farxiga far-SEE-guh in the U.S. and Forxiga in the EU and Russia) is a drug of the gliflozin class, used to treat type 2 diabetes. It was developed by Bristol-Myers Squibb in partnership with AstraZeneca. Contents 1 Medical uses 2 Side effects 3 Mechanism of action 3.1 Selectivity 4 Research 5 References 6 External links Medical uses In July 2011 a U.S. Food and Drug Administration (FDA) endocrinologic and metabolic drugs advisory comm...

Read more Qtern Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Dapagliflozin

Recent Qtern Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Dapagliflozin + Saxagliptin
  • Tablet: 10mg + 5mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

Drugs with one or more similar ingredients: (9 results)